Antigen-specific immunotherapy with thyrotropin receptor peptides in Grave's Hyperthyroidism: a Phase I study

Thumbnail Image
Files
Pearce_Thyroid.pdf (581.47 KB)
URI
https://hdl.handle.net/11287/621091
Authors
Vaidya, Bijay
Journal
Thyroid
Type
Journal Article
Publisher
Mary Ann Liebert
DOI
10.1089/thy.2019.0036
Rights
This Open Access article is distributed under the terms of the Creative Commons License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Graves' disease is one of the most common autoimmune conditions, but treatment remains imperfect. This study explores the first-in-human use of antigen-specific immunotherapy with a combination of two thyrotropin receptor (TSHR) peptides (termed ATX-GD-59) in Graves' hyperthyroidism.
Citation
Pearce SHS [et al]. Antigen-specific immunotherapy with thyrotropin receptor peptides in Grave's Hyperthyroidism: a Phase I study.Thyroid. 2019 Jul;29(7):1003-1011
Publisher URL
https://www.ncbi.nlm.nih.gov/pmc/articles/pmid/31194638/
Note
This article is freely available via Open Access. Click on the Publisher's URL to access the full-text via the publisher's site.
Collections
2019 RD&E publications
Diabetes and endocrinology